Avac Event

MTN-017: Evolution and Implementation

IRMA, AVAC and the Microbicide Trials Network (MTN) provided an update on the Phase II safety and acceptability study MTN 017 (now closed to accrual) and looked at potential future directions for rectal microbicide research. MTN’s Dr. Ross Cranston, Protocol Chair for MTN-017, walked participants through the evolution and implementation of 017 – the world’s first-ever Phase II rectal microbicide trial. Next, Dr. Ian McGowan, Co-Principal Investigator of the MTN discussed ideas and directions for what the rectal future may hold in terms of advanced stage trial design and planning.